Dr. Audeh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
14816 OTSEGO ST
Sherman Oaks, CA 91403Phone+1 310-849-0561- Is this information wrong?
Summary
- Chief Medical Officer, Agendia, Inc.
Breast Cancer Genomics
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1986 - 1989
- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1982 - 1986
- University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1982
Certifications & Licensure
- CA State Medical License 1983 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2014
- Top Doctors:LA Area Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2013
- Join now to see all
Clinical Trials
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
- A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients Start of enrollment: 2014 Feb 25
- Join now to see all
Publications & Presentations
PubMed
- 216 citationsEfficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M. Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, Rita K. Schmutzler, M. William Audeh
Gynecologic Oncology. 2016-02-01 - 1231 citationsOlaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 MutationBella Kaufman, Ronnie Shapira-Frommer, Rita K. Schmutzler, M. William Audeh, Michael Friedlander
Journal of Clinical Oncology. 2015-01-20 - 150 citationsOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell
Lancet. 2010-07-24
Professional Memberships
- Member
Hospital Affiliations
- Cedars-Sinai Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: